Baxdrostat

Baxdrostat
Identifiers
	IUPAC name N-[(8R)-4-(1-methyl-2-oxo-3,4-dihydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]propanamide;
CAS Number	1428652-17-8;
PubChem CID	71535962;
IUPHAR/BPS	12362;
ChemSpider	76804781;
UNII	NF3P9Z8J5Y;
KEGG	D12789;
ChEMBL	ChEMBL4113975;
Chemical and physical data
Formula	C22H25N3O2
Molar mass	363.461 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(=O)N[C@@H]1CCCC2=C1C=NC=C2C3=CC4=C(C=C3)N(C(=O)CC4)C;
	InChI InChI=InChI=1S/C22H25N3O2/c1-3-21(26)24-19-6-4-5-16-17(12-23-13-18(16)19)14-7-9-20-15(11-14)8-10-22(27)25(20)2/h7,9,11-13,19H,3-6,8,10H2,1-2H3,(H,24,26)/t19-/m1/s1; Key:VDEUDSRUMNAXJG-LJQANCHMSA-N;

Baxdrostat is an investigational drug that is being evaluated for the treatment of hypertension.^[1] It is an aldosterone synthase inhibitor.^[2]^[3]

References

^ "Baxdrostat - CinCor Pharma". AdisInsight. Springer Nature Switzerland AG.
^ Dogra S, Shah S, Gitzel L, Pusukur B, Sood A, Vyas AV, Gupta R (July 2023). "Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension". Current Problems in Cardiology. 48 (11): 101918. doi:10.1016/j.cpcardiol.2023.101918. PMID 37399857. S2CID 259320969.
^ Awosika A, Cho Y, Bose U, Omole AE, Adabanya U (October 2023). "Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension". Expert Opinion on Investigational Drugs. 32 (11): 985–995. doi:10.1080/13543784.2023.2276755. PMID 37883217. S2CID 264517675.